-+ 0.00%
-+ 0.00%
-+ 0.00%
Innate Pharma reports preliminary antitumor activity for IPH4502 in Phase 1 trial
Share
Listen to the news
Innate Pharma reports preliminary antitumor activity for IPH4502 in Phase 1 trial
  • Innate Pharma presented initial Phase 1 results for IPH4502 in advanced solid tumors today at ENA 2026.
  • The experimental Nectin-4-targeting antibody-drug conjugate showed preliminary antitumor activity across several tumor types, including urothelial cancer previously treated with enfortumab vedotin.
  • Safety findings showed low overall blood-related toxicity, with stomatitis the only reported dose-limiting toxicity.
  • Dose optimization will focus on previously treated urothelial cancer, with the first patient expected in the first half of 2027.
  • The next stage will test split dosing with mandatory stomatitis prevention to guide selection of a Phase 2 regimen.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innate Pharma SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20261117909426) on November 18, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending